Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is plea
Biotechnology, Pharmaceuticals, Health
2026-08-20 9:44 AM EDT | Hemostemix Inc.
Maxwell Biosciences' Spinout SHU.ai Announces Closing of $1M Financing Round
Austin, Texas--(Newsfile Corp. - August 20, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers®, December 5, 2025 incorporated its first spinout SHU.ai and June 27, 2026 announced the closing of SHU's $1 million Seed round. The round was oversubscribed and fully funded by private angel investors and led by Keiretsu Forum, "The World's Largest Angel Investor Network." The funds will support accelera
Biotechnology, Pharmaceuticals
2026-08-20 9:00 AM EDT | Maxwell Biosciences, Inc.
TempraMed Announces Extension of Maccabi Healthcare Services Agreement
Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance organization ("HMO"), has exercised its option to extend its agreement with TempraMed for an additional year u
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-20 7:00 AM EDT | TempraMed Technologies Ltd.
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced the appointment of Mahan Chehrenama, DO, as Chief Medical Officer. Dr. Chehrenama will lead clinical development for BETR-001, the Company's non-hallucinogenic neuroplastogen advancing toward an Investigational New Drug (IND) appli
2026-08-19 8:00 AM EDT | BetterLife Pharma Inc.
Telescope Announces Appointment of Dr. E. Neil Lewis to the Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (the "Company" or "Telescope"), a leading developer of Physical AI systems, including Self-Driving Laboratories, and enabling technologies and services for the global pharmaceutical and high-value chemical industries, is pleased to announce the appointment of Dr. Neil Lewis to its Board of Directors (the "Board"), effective August 19, 2026.
Technology, Chemical, Pharmaceuticals
2026-08-19 8:00 AM EDT | Telescope Innovations Corp.
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and regul
Biotechnology, Pharmaceuticals
2026-08-19 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Richards Group Inc. Announces August 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended August 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on August 31, 2026 and will be payable on September 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-08-18 11:12 AM EDT | Richards Group Inc.
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or
Biotechnology, Pharmaceuticals
2026-08-18 8:00 AM EDT | PharmaTher Holdings Ltd.
PharmaCorp Closes Previously Announced Western Canada Pharmacy Acquisition and Announces Two Additional Definitive Agreements
Purchase price of approximately $2.47 million Acquisition increases PharmaCorp's operating network to 16 pharmacies New definitive share purchase agreement executed for a PharmaChoice Canada-bannered pharmacy in Western Canada at a purchase price of approximately $1.3 million New definitive asset purchase agreement executed for the prescription files of an I.D.A.-bannered pharmacy in Western Canada Saskatoon, Saskatchew
Biotechnology, Pharmaceuticals, Retail
2026-08-18 8:00 AM EDT | PharmaCorp RX Inc.
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-18 7:00 AM EDT | TempraMed Technologies Ltd.
Custom Health Achieves 70% Increase in Quarterly Revenue in Q2-2026 and Advances Medication Management Platform with Evergreen Pharmacy and Spencer Health Solutions Acquisitions
For the three months ended June 30, 2026, Custom Health achieved quarterly revenue of US$7.4 million, an increase of 70% from Q2-2025. The results reflect the acquisition of InnovativeRx during the period. The equity pickup for IRX accounts for an acquisition date of June 5, 2026. Proforma Revenue for the combined entity for the 3 months ended June 30, 2026 is US$14.3 million(1). Subsequent to quarter-end, Custom Health entered into a binding letter
Technology, Pharmaceuticals, Health
2026-08-17 6:07 PM EDT | Custom Health Holdings Inc.
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthening the Company's leadership and deve
Biotechnology, Pharmaceuticals, Health
2026-08-17 3:15 AM EDT | Defence Therapeutics Inc.
Richards Group Inc. Announces Change of Auditor
Toronto, Ontario--(Newsfile Corp. - August 15, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") today announced that its Board of Directors (the "Board"), on the recommendation of the Audit Committee, has approved the appointment of Ernst & Young LLP, Chartered Professional Accountants ("Successor Auditor") as the Company's auditor, replacing PricewaterhouseCoopers LLP ("Former Auditor"), effective August 10, 2026. The change followed a review of the Company's external audit require
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-08-15 8:15 PM EDT | Richards Group Inc.
Hanf.com Transaction Advances as Neural Therapeutics Receives CSE Conditional Approval
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of the Company's shares following completion of its previously announced fundamental change transaction involving CWE European Holdings Inc. ("CWE"), which operates the Hanf.com business in Germany (
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-08-14 5:01 PM EDT | Neural Therapeutics Inc.
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027
Halifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars unless otherwise stated. "While ATI-1801 remains the Company's principal
Biotechnology, Pharmaceuticals, industries.supplementary-medicine.name
2026-08-14 5:00 PM EDT | Appili Therapeutics Inc.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2026, were $32.4 million, a decrease of $7.9 million or approximately 19.5% as compared to the same period of the pri
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-13 4:11 PM EDT | Elite Pharmaceuticals, Inc.
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial. The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular h
Biotechnology, Pharmaceuticals, Health
2026-08-12 8:23 AM EDT | Hemostemix Inc.
Project Farma Acquires SimoTech, Bringing End-to-End GMP Automation and Digital Manufacturing to Life Sciences Customers
Shelton, Connecticut--(Newsfile Corp. - August 11, 2026) - Acquisition brings together PerkinElmer's Project Farma's CQV, project delivery, and quality expertise with SimoTech's DCS, MES, SCADA, and GMP IT experience to strengthen global manufacturing services platform. Project Farma, PerkinElmer's leading provider of Good Manufacturing Practice (GMP) manufacturing services, today announced it has entered into a definitive agreement to acquire SimoTech, a trusted provider of manufa
2026-08-11 10:10 AM EDT | PerkinElmer
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced the establishment of PERSONALIZ3D™, an integrated ecosystem that will combine telehealth, pharmaceutical 3D printing, and pharmacy fulfillment to support the delivery of personalized medicines. PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D P
Biotechnology, Pharmaceuticals
2026-08-11 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio. The patent allowance represents a critical milestone in protecting Phio's stra
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-11 7:00 AM EDT | Phio Pharmaceuticals Corp.